Recent Insights into the Biomarkers, Molecular Targets and Mechanisms of Non-Alcoholic Steatohepatitis-Driven Hepatocarcinogenesis

被引:7
作者
Kakehashi, Anna [1 ]
Suzuki, Shugo [1 ]
Wanibuchi, Hideki [1 ]
机构
[1] Osaka Metropolitan Univ, Dept Mol Pathol, Grad Sch Med, 1-4-3 Asahi Machi, Abeno Ku, Osaka 5458585, Japan
关键词
NAFLD; NASH; HCC; biomarker; hepatocarcinogenesis mechanisms; FATTY LIVER-DISEASE; CHAIN AMINO-ACIDS; HEPATOCELLULAR-CARCINOMA; DOWN-REGULATION; INTERACTING PROTEIN; COREGULATOR RIP140; HEPATIC STEATOSIS; SERUM BIOMARKER; GROWTH; HCC;
D O I
10.3390/cancers15184566
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary This review is focused on the research recently published in the field of non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), and steatohepatitis (NASH)-associated liver cancer. We aimed to highlight recent omics research on novel genetic and protein contributions to NAFLD/NASH to discuss the mainstream molecular pathways and novel candidate biomarkers and molecular targets in NAFLD/NASH. Special attention is paid to the role mTOR, as multifunctional orchestrator in NASH progression to HCC.Abstract Non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (NASH) are chronic hepatic conditions leading to hepatocellular carcinoma (HCC) development. According to the recent "multiple-parallel-hits hypothesis", NASH could be caused by abnormal metabolism, accumulation of lipids, mitochondrial dysfunction, and oxidative and endoplasmic reticulum stresses and is found in obese and non-obese patients. Recent translational research studies have discovered new proteins and signaling pathways that are involved not only in the development of NAFLD but also in its progression to NASH, cirrhosis, and HCC. Nevertheless, the mechanisms of HCC developing from precancerous lesions have not yet been fully elucidated. Now, it is of particular importance to start research focusing on the discovery of novel molecular pathways that mediate alterations in glucose and lipid metabolism, which leads to the development of liver steatosis. The role of mTOR signaling in NASH progression to HCC has recently attracted attention. The goals of this review are (1) to highlight recent research on novel genetic and protein contributions to NAFLD/NASH; (2) to investigate how recent scientific findings might outline the process that causes NASH-associated HCC; and (3) to explore the reliable biomarkers/targets of NAFLD/NASH-associated hepatocarcinogenesis.
引用
收藏
页数:29
相关论文
共 152 条
  • [1] Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful
    Abdelhamed, Walaa
    El-Kassas, Mohamed
    [J]. JOURNAL OF VIRAL HEPATITIS, 2023, 30 (02) : 148 - 159
  • [2] Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis
    Ahmed, Eman A.
    El-Derany, Marwa O.
    Anwar, Ali Mostafa
    Saied, Essa M.
    Magdeldin, Sameh
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
  • [3] Role of gut microbiota in liver disease
    Albhaisi, Somaya A. M.
    Bajaj, Jasmohan S.
    Sanyal, Arun J.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2020, 318 (01): : G84 - G98
  • [4] The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: New insights and future directions
    Alshehade, Salah
    Alshawsh, Mohammed Abdullah
    Murugaiyah, Vikneswaran
    Asif, Muhammad
    Alshehade, Omayma
    Almoustafa, Hassan
    Al Zarzour, Raghdaa Hamdan
    [J]. LIFE SCIENCES, 2022, 305
  • [5] From NASH to HCC: current concepts and future challenges
    Anstee, Quentin M.
    Reeves, Helen L.
    Kotsiliti, Elena
    Govaere, Olivier
    Heikenwalder, Mathias
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (07) : 411 - 428
  • [6] Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future
    Araujo, Ana Ruth
    Rosso, Natalia
    Bedogni, Giorgio
    Tiribelli, Claudio
    Bellentani, Stefano
    [J]. LIVER INTERNATIONAL, 2018, 38 : 47 - 51
  • [7] Armandi A, 2022, HANDB EXP PHARMACOL, V274, P253, DOI 10.1007/164_2021_561
  • [8] MSAP is a novel MIR-interacting protein that enhances neurite outgrowth and increases myosin regulatory light chain
    Bornhauser, BC
    Olsson, PA
    Lindholm, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (37) : 35412 - 35420
  • [9] Loss of Ufl1/Ufbp1 in hepatocytes promotes liver pathological damage and carcinogenesis through activating mTOR signaling
    Chen, Fanghui
    Sheng, Le
    Zhou, Tianci
    Yan, Li
    Loveless, Reid
    Li, Honglin
    Teng, Yong
    Cai, Yafei
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023, 42 (01)
  • [10] Progress in Research on CNPY2 in Diseases
    Chen, Ke-qian
    Zhang, Yu-qing
    Wang, Zong-bao
    Wang, Shu-zhi
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2024, 24 (04) : 391 - 402